Regeneron

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Regeneron 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About REGN

Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: Dupixent, Evkeeza, Eylea, Inmazeb, and Kevzara. 

CEO
Leonard S. Schleifer
CEOLeonard S. Schleifer
Employees
15,410
Employees15,410
Headquarters
Tarrytown, New York
HeadquartersTarrytown, New York
Founded
1988
Founded1988
Employees
15,410
Employees15,410

REGN Key Statistics

Market cap
77.27B
Market cap77.27B
Price-Earnings ratio
18.59
Price-Earnings ratio18.59
Dividend yield
0.49%
Dividend yield0.49%
Average volume
873.41K
Average volume873.41K
High today
$747.37
High today$747.37
Low today
$747.37
Low today$747.37
Open price
$745.15
Open price$745.15
Volume
99.00
Volume99.00
52 Week high
$859.34
52 Week high$859.34
52 Week low
$541.00
52 Week low$541.00

Stock Snapshot

With a market cap of 77.27B, Regeneron(REGN) trades at $747.37. The stock has a price-to-earnings ratio of 18.59 and currently yields dividends of 0.49%.

As of 2026-09-30, Regeneron(REGN) stock has fluctuated between $747.37 and $747.37. The current price stands at $747.37, placing the stock 0.0% above today's low and 0.0% off the high.

Regeneron(REGN) shares are trading with a volume of 99, against a daily average of 873.41K.

In the last year, Regeneron(REGN) shares hit a 52-week high of $859.34 and a 52-week low of $541.00.

In the last year, Regeneron(REGN) shares hit a 52-week high of $859.34 and a 52-week low of $541.00.

REGN News

24/7 Wall St. 1h
A $32 Biotech Became a $90 Biotech Overnight. Is It Too Late to Buy Kodiak? - 24/7 Wall St.

...

A $32 Biotech Became a $90 Biotech Overnight. Is It Too Late to Buy Kodiak? - 24/7 Wall St.
Simply Wall St 18h
What Is Regeneron Pharmaceuticals Facing After A Rival Matched Its Key Eye Drug?

Kodiak Sciences reported Phase 3 data showing Zenkuda matched Regeneron Pharmaceuticals (NasdaqGS:REGN) eye drug Eylea in macular degeneration. The trial used...

What Is Regeneron Pharmaceuticals Facing After A Rival Matched Its Key Eye Drug?
Zacks 22h
REGN or ILMN: Which Is the Better Value Stock Right Now?

Investors interested in Medical - Biomedical and Genetics stocks are likely familiar with Regeneron (REGN Quick QuoteREGN - Free Report) and Illumina (ILM...

REGN or ILMN: Which Is the Better Value Stock Right Now?

Analyst ratings

60%

of 30 ratings
Buy
60%
Hold
33.3%
Sell
6.7%

More REGN News

TipRanks 1d
Court Dismisses Regeneron Pharmaceuticals Securities Lawsuit Over Eylea and Eylea HD Claims

A federal judge has dismissed a securities fraud lawsuit against Regeneron Pharmaceuticals (REGN) and several of its executives, with the court directing the Cl...

The Wall Street Journal 2d
Under the Radar: Kodiak Shares Surge as Eye Drug Matches Regeneron's

Shares of Kodiak Sciences surged more than 170% Monday—on pace for its largest one-day increase on record—after the company announced its eye drug matched Regen...

Under the Radar: Kodiak Shares Surge as Eye Drug Matches Regeneron's
Nasdaq 2d
Should You Buy Regeneron Pharmaceuticals Stock Before Oct. 30?

Key Points Regeneron's stock has underperformed the market this year, but it got a boost last time it reported earnings. The company's revenue grew by 17% las...

Should You Buy Regeneron Pharmaceuticals Stock Before Oct. 30?
TipRanks 2d
Kodiak data raises competitive bar for Regeneron, says Citi

Citi says shares of Regeneron (REGN) are down after Kodiak Sciences’ (KOD) Zenkuda delivered non-inferior vision gains versus aflibercept in a Phase 3 wet age-r...

Benzinga 2d
Regeneron Eylea Feels the Pinch as Kodiak Advances Extended Dosing for Eye Drug

Regeneron Pharmaceuticals Inc.’s (NASDAQ:REGN) stock is trading lower on Monday, probably in reaction to positive data from Kodiak Sciences Inc.’s (NASDAQ:KOD)...

Regeneron Eylea Feels the Pinch as Kodiak Advances Extended Dosing for Eye Drug
Benzinga 2d
Kodiak Sciences Says Eye Drug on Par with Regeneron's Medicine

Kodiak Sciences Inc. (NASDAQ:KOD) on Monday released data from the Phase 3 DAYBREAK trial for patients suffering from wet age-related macular degeneration (wAMD...

Kodiak Sciences Says Eye Drug on Par with Regeneron's Medicine
Investor's Business Daily 2d
Why Regeneron Rival Kodiak Sciences Just Skyrocketed 90%-Plus

Oil Shipper Hits New High; Three Stocks Also Near Pivots 8/21/2026 Oil transportation stock Frontline is at a new high in Friday's stock market. Advantest, Reg...

Why Regeneron Rival Kodiak Sciences Just Skyrocketed 90%-Plus

People also own

Based on the portfolios of people who own REGN. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.